An amplified enzyme-linked immunosorbent assay (amp-ELISA) was compared with the AOAC Official Method 977.26 for detection of Clostridium botulinum and its toxins in foods. Eleven laboratories participated and the results of 10 laboratories were used in the study. Two anaerobic culture media, tryptone peptone glucose yeast extract (TPGY) and cooked meat medium (CMM) were used to generate toxic samples with types A, B, E, and F botulinal strains. Nonbotulinal clostridia were also tested. The toxicity of each botulinal culture was determined by the AOAC method, and the cultures were then diluted, if necessary, to high (about 10 000 minimal lethal dose [MLD]/mL) and low (about 100 MLD/mL) test samples. The overall sensitivity of detection in TPGY and CMM cultures with the amp-ELISA was 94.7% at about 100 MLD/mL and 99.6% for samples with ³10 000 MLD/mL toxicity. The amp-ELISA detection sensitivity for low toxin samples was 92.3% in TPGY and 99.4% in CMM. The false-positive rate ranged from 1.5% for type A to 28.6% for type F in TPGY, and from 2.4% for type A to 11.4% for type F in CMM. Most of the cross-reactivity was due to detection of other botulinal types, especially in high toxin samples. The amp-ELISA could be used to screen suspect cultures for botulinal toxins. Positive amp-ELISA samples would be confirmed by the AOAC reference method.
A collaborative validation study was conducted to compare the performance of the amplified enzyme-linked immunosorbent assay (amp-ELISA) with the mouse bioassay method (AOAC Official Method 977. 26 for Clostridum botulinum and its toxins in foods) for detection of types A, B, E, and F botulinal toxins produced in culture media. The intended use of this procedure is the determination of botulinal toxin production in broth media, tryptone peptone glucose yeast extract (TPGY) and cooked meat medium (CMM), which are the prescribed media for the AOAC Official Method.
Currently, the AOAC mouse bioassay method (1) is the only approved method for detection of botulinal toxin during investigations of botulism. Although highly sensitive, this method is limited, requiring up to 6 days to obtain final results and conducted only in facilities that have mice available for the test. The requirement for mice severely limits the number of test sites around the country and results in the use of thousands of mice each year in approved laboratories. An alternative in vitro method would facilitate botulism investigations by increasing the number of available test laboratories and reducing the number of animals needed for these studies.
The ELISA is a sandwich type procedure that results in the indirect detection of types A, B, E, and F botulinal toxins. Polyclonal antibodies to the 4 toxin types used in the amp-ELISA are produced by using immunoglobulins purified by Protein G chromatography. Each toxin type-specific IgG is coated onto microtiter plates and used as a capture antibody for each homologous toxin. Following addition of culture supernatants, specific IgGs are also used as a secondary antibody (biotinylated form) that binds to captured toxin. The biotin residues on the secondary IgG are then detected by using streptavidin conjugated to alkaline phosphatase and an ampli-fied substrate (2, 3) . Positive and negative controls are used to monitor color development. The method uses 2 media that are recommended in the current AOAC method for the growth of botulinal organisms and synthesis of toxins (1) .
A previous study (2) demonstrated that the amp-ELISA is effective for the detection of types A, B, E, and F botulinal toxins in culture media. In a precollaborative study this system detected toxin in culture media at approximately the 10 mouse minimal lethal dose (MLD)/mL level (2) . The present report describes the multilaboratory collaborative study that compared the amp-ELISA with the mouse bioassay method for detection of botulinal toxins in culture media.
Experimental Design
This method was tested in a precollaborative study that demonstrated its inclusivity/exclusivity for each of the botulinal toxin types in cultures of TPGY and CMM (2) . The multilaboratory study is presented in this report.
Nonbotulinal and relatively high and low toxin levels for a variety of botulinal cultures were tested with the amp-ELISA after their toxicity was determined by the mouse bioassay reference method.
Collaborative Study

Test Organisms
Botulinal and nonbotulinal toxin-producing strains were provided by H. Solomon (U.S. Food and Drug Administration, College Park, MD) and C. Hatheway (Centers for Disease Control and Prevention, Atlanta, GA). Six type A, 6 proteolytic and 6 nonproteolytic type B, 6 type E, and 6 proteolytic and 5 nonproteolytic type F botulinal toxin-producing strains were tested. Five nonbotulinal toxin-producing strains were examined: 3 C. sporogenes, one C. perfringens, and one C. novyi. Eleven laboratories agreed to test each sample by ELISA. The mouse bioassay was performed on inoculated cultures only in the laboratory of the Study Director.
Preparation of Test Samples
The TPGY and CMM cultures were incubated according to the current AOAC method (1) . The media were inoculated and incubated for 5 days at the FDA Southeast Regional Laboratory (Atlanta, GA; TPGY at 26 ± 2°C and CMM at 35 ± 2°C), clarified by centrifugation, filtered, and stored frozen for future amp-ELISA and mouse bioassay testing. Toxicity of TPGY and CMM was determined at the University of Wisconsin (Madison, WI) by the AOAC method before shipment to the collaborating laboratories. The original culture fluid was then thawed and diluted (if necessary) using sterile TPGY or CMM to contain low (about 100 MLD/mL) and high (about 10 000 MLD/mL) levels of toxin. Some samples were determined to be <100 MLD/mL (0-10 MLD/mL) and were tested undiluted as high and low toxin samples. The toxic samples (about 1 mL) were placed in small tubes and frozen before shipment to the participating laboratories for analysis. The toxicities of these samples are shown in Table 1 . Each sample was analyzed without further dilution.
Shipment of Test Samples
The samples were shipped on dry ice by overnight carrier in numbered, color-coded tubes except for the positive (types A, B, E, and F toxins) and negative (uninoculated media) controls that were identified as such. The samples were held at freezer temperature (-20 ± 3°C) until tested.
Shipment of Materials for the Study
Microtiter plates, bicarbonate buffer reagent, coating IgG, casein, biotinylated IgG, Extravidin-alkaline phosphatase conjugate, Tris and phosphate-buffered saline (PBS) buffers, Tween 20, and amplified substrate were sent to each of the participating laboratories under appropriate shipping temperature by overnight carrier. Storage temperature instructions were included for the reagents.
Analysis
All collaborators were required to provide standard operating procedures for safely handling, disposing, and inactivating material containing botulinal toxin. Collaborators were required to autoclave waste material at 121°C for 60 min. Frozen samples were thawed to room temperature and shaken before analysis. They were analyzed undiluted. One day was required to complete each part of the 4-part study after microtiter plates were prepared (total of 4 days). Each sample was analyzed undiluted in duplicate for each toxin type by the participating laboratories.
The study was divided into 4 parts. Part 1 consisted of high toxin samples produced in TPGY medium (#10 000 MLD/mL); part 2 used high toxin samples generated in CMM (#10 000 MLD/mL); part 3 consisted of low toxin samples in TPGY (#100 MLD/mL); part 4 used low toxin samples in CMM (#100 MLD/mL). Each part of the 4-part study consisted of 40 unknowns for a total of 160 unknowns. Each unknown was analyzed for each of the 4 toxin types (A, B, E, and F) for a total of 640 analyses by each laboratory. Raw data and data recorded on reporting sheets were sent to the Study Director at the FDA Southeast Regional Laboratory.
Statistical Analysis of Data
A McNemar paired statistical analysis of the methods was performed for each toxin type and for each of the 2 culture media (4). The reference method was assumed to be positive in the hands of each laboratory, although the toxicity of the samples was determined in the Study Director's laboratory. A Chi square value >3.84 was indicative of a significant difference at the 5% probability level. The sensitivity, specificity, and percent agreement were determined by the method of McClure (5) .
An Unweighted Pair-Group Method Using Arithmetic Averages was used to evaluate interlaboratory agreement of the ELISA (6) . Simple matching coefficients were determined by the following formula for each laboratory pair: (a + d)/(a + b + c + d), where a = the number of tests that were positive in both laboratories; b = the number of tests that were positive in Laboratory A and negative in Laboratory B; c = the number of tests that were positive in Laboratory B and negative in Laboratory A; and d = the number of tests that were negative in both laboratories. A coefficient of 1.0 indicated complete data agreement.
Coefficients were calculated between all possible pairs of laboratories for each data set (e.g., type A, TPGY). A statistical software package (SAS Version 8; SAS Institute Inc., Cary, NC) was used to determine the coefficients and then to perform sequential calculations (Unweighted Pair-Group Method) to cluster laboratories with similar data. A similarity coefficient of 0.90 (90%) was chosen as the cutoff for the laboratory comparisons because this indicated that each laboratory was in agreement on $90% of the samples. Any similarity coefficient $90% indicated interlaboratory agreement in the ELISA results. 
A. Principle
The method is designed to detect types A, B, E, and F botulinal toxins from undiluted cultures of TPGY and CMM media using a sandwich ELISA. Toxins are captured by IgGs coated on microtiter plates and detected by using biotinylated IgGs and a streptavidin alkaline phosphatase conjugate. The bound enzyme is then observed by using an amplified substrate. b High = high toxin samples; low = low toxin samples; Non-A = non-type A toxin-producing culture samples; Non-B = non-type B toxin-producing culture samples; Non-E = non-type E toxin-producing culture samples; Non-F = non-type F toxin-producing culture samples. b High = high toxin samples; low = low toxin samples; Non-A = non-type A toxin-producing culture samples; Non-B = non-type B toxin-producing culture samples; Non-E = non-type E toxin-producing culture samples; Non-F = non-type F toxin-producing culture samples.
B. Apparatus
C. Reagents
(a) 0.05M Carbonate-bicarbonate buffer.-pH 9.6 ± 0.1. Dissolve contents of one bicarbonate capsule (Cat. No. C-3041; Sigma, St. Louis, MO) in 100 mL distilled water or equivalent.
(b) 1.0% Casein buffer.-Add one packet phosphate-buffered saline (PBS) powder (Sigma; Cat. No. P3813) to 800 mL distilled water, 10 g vitamin-free casein (Research Organics, Cleveland, OH 44125-1083, www.resorg.com; Cat. No. 1087C), and 3 mL 1M NaOH (4.0 g NaOH/100 mL water); heat with stirring to ca 80°C. Adjust to pH 7.9 ± 0.1 with 1M NaOH; then dilute to 1 L. Sterilize at 121°C for 20 min. Final pH should be 7.6 ± 0.1. 
D. Analysis
Safety.-Botulinal toxins are extremely toxic to humans. Minute quantities acquired by ingestion, inhalation, or by absorption through the eye or a break in the skin can cause profound intoxication and death. Laboratory personnel should be immunized with the botulinum toxoid vaccine available through CDC. After use, rinse the plate washer with distilled water, using a maintenance protocol; collect the waste in the waste reservoir with other washer waste and autoclave at 121°C for 60 min. There is no detectable toxin in the washer tubing after normal use of the equipment.
Amplified ELISA procedure.-Prepare 1 microtiter plate, B(a), for each toxin type to be tested. Identify each plate as type A, B, E, or F. Using a micropipettor, B(d), to measure the stock antitoxins, dilute the antitoxins, C(c), with bicarbonate buffer, C(a), in glass test tubes as specified by supplier. Transfer diluted antitoxins to multichannel pipet reservoirs, B(j). Using an 8-place multichannel pipettor, B(c), and reservoirs, dispense into each well of each of the microtiter plates 100 mL of the appropriate dilution of type A, B, E, or F antitoxins. Four plates (one of each type: A, B, E, and F) are needed.
Cover plates with a plastic seal, B(b), and store at 4 ± 2°C overnight.
Remove plates from 4 ± 2°C storage and wash each plate 5 times in TBS-T, C(e), with a 45 ± 5 s delay between washes. Use a plate washer, B(f), or other mechanical device; do not use a squeeze bottle to wash. Block plates in casein buffer, C(b), by filling all wells to the top (ca 300 µL/well) and incubate for 60-90 min at 35 ± 2°C, B(e). Do not wash the plate. Thaw frozen test cultures at room temperature while the plate is being blocked. Discard the casein buffer, tamp plate, and then add the thawed room-temperature toxic test samples and controls to duplicate wells (100 mL/well). Work from left to right side of plate when adding reagents.
Incubate plates with the toxin-containing test cultures and controls for 2 h ± 5 min at 35 ± 2°C.
Incubate in duplicate the known type specific A, B, E, and F controls on the homologous plates. Incubate 100 mL of casein buffer in duplicate wells instead of test cultures or controls for a blank control. Prepare types A, B, E, and F biotin-labeled antibody reagents, C(d), according to attached instructions 15-30 min before use while incubating tests. Dilute biotinylated antitoxins in casein buffer according to attached instructions. Wash plates 5 times in TBS-T as above. Add diluted type A, B, E, or F biotinylated antitoxin (100 mL/well) to appropriate labeled homologous plates and incubate for 60 ± 5 min at 35 ± 2°C.
Wash plates 5 times in TBS-T as above. Add 100 mL of previously diluted ExtraVidin-alkaline phosphatase conjugate, C(f), (diluted 1 mL/10 mL casein buffer) to each well and incubate for 60 ± 5 min at 35 ± 2°C. Wash 5 times in TBS-T with a final 10 ± 2 min soak in wash buffer, C(b). Discard wash buffer and tamp plate on paper towels to remove buffer. Reconstitute GIBCO substrate and amplifier solutions by adding proper liquid diluents to the lyophilized substrate and amplifer bottles, C(g). Use the manufacturer's directions for this product. Add 50 mL GIBCO substrate solution, and incubate 11-13 min at 25 ± 2°C on plate shaker, B(g), (ca 100 rpm); then add 50 mL GIBCO amplifier and incubate 2-10 min without shaking.
Reading the plate.-Add amplifier solution to plate near a plate reader, B(h). Read absorbance at 490 and 630 nm (reference filter) when positive controls reach absorbance of 0.8-1.2 and negative controls are acceptable. Subtract A 630 from A 490 . Stop analysis (color development) by adding 50 mL 0.3M H 2 SO 4 , C(h); the absorbance may be read later (up to 2 h). The stop reagent is added at any time (2-12 min) after addition of amplifier when positive controls give an absorbance ca 1.0 and negative controls are acceptable (not >0.2 above background levels).
Interpretation of test results.-A positive test is an absorbance value that is >0.2 above the absorbance observed in the negative control wells. There may be slight cross-reactivity between toxic samples. If the plates are not washed adequately, higher background absorbance will be observed in all wells. 
Confirmation of results.-Positive
Results
Eleven laboratories participated in the study. Ten laboratories submitted acceptable results; the data from one laboratory were not used because of high background and erratic absorbance values. The collaborator cited inadequate washing by the automatic plate washer as a possible cause of the poor results.
Overall, 1192 ELISA tests were performed on samples that contained at least 1 MLD/mL types A, B, E, or F toxins. The overall sensitivity of the ELISA (TPGY and CMM samples combined) was 94.7% for all samples with $100 MLD/mL toxicity. When divided by culture medium, the sensitivity of the ELISA at the 100 MLD/mL toxin was 92.3% in TPGY samples and 99.4% in CMM samples. Toxin production was lower for types E and F in CMM cultures than in TPGY cultures ( Table 1 ). The sensitivity of the AOAC reference method was 100% for TPGY samples but only 72% for CMM samples.
The sensitivity of the ELISA was excellent in all cultures that contained $100 MLD/mL toxin ( Table 2 ). The amp-ELISA detection sensitivity for high toxin samples (10 000 MLD/mL) by growth medium type was 99.6% in TPGY and 99.4% in CMM. All of the cultures were positive by the ELISA test in at least one of the 2 culture media. Tables 2002.08A and B provide a summary of the results for the interlaboratory study for each toxin type at the 1 MLD/mL level. The tables show that in most of the comparisons there was a significant difference between the ELISA and the reference method. In general, the differences were due to lower specificity of the ELISA. However, some differences, particularly in the types E and F cultures, were due to the inability of the ELISA to detect toxin levels from 1 to 10 MLD/mL. The reference method also did not detect some toxic strains in CMM that were positive with the ELISA.
Analysis of Type A Botulinal Cultures
The ELISA from the 10 laboratories did not differ for detection of positive type A samples (100% sensitivity) compared to the reference method for high or low toxin samples in TPGY (Table 3) or CMM ( Table 4) . One of the CMM cultures (33A) was also negative in the mouse bioassay (Table 4) . Cross-reactivity between all the samples (toxic and nontoxic) was higher in the high toxin samples than in the low toxin samples (Tables 2002.08A and B) . Although Chi square analyses suggested significant differences between the ELISA and the reference method, agreement between the 2 methods was about 95% with both high and low toxin samples (Tables 2002.08A and B). Cross-reactivity with non-type A culture supernatants was <4.2% (Tables 2002.08A and B). The interlaboratory comparison of the ELISA (Unweighted Pair-Group Method) was excellent, with similarity coefficients >90% for all laboratories in each test group (TPGY, high/low, and CMM, high/low).
Analysis of Type B Botulinal Cultures
The ELISA data for detection of type B positive samples differed slightly (59 out of 60 positive tests) from the reference method for high or low toxin samples from proteolytic strains in TPGY (Table 5) or CMM (Table 6) . For nonproteolytic strains, there was little difference in the TPGY or CMM high toxin samples. The detection of low nonproteolytic toxin samples in TPGY (45 positive out of 60 tests) and CMM (51 positive out of 60 tests) was less than the reference method. One of the low toxin TPGY samples (Kap 5B) contained <100 MLD/mL (10 MLD/mL; Table 1) , and only 2 of the 10 ELISA results were positive for this sample (Table 5) . Two of the low toxin CMM samples (17B and 17780 B) contained <10 MLD/mL, and 12 of 20 ELISA results were positive for these samples. Cross-reactivity with non-type B samples was <8.9%. Interlaboratory comparison of the ELISA was generally excellent with similarity coefficient $90%. The results from Collaborator 4 differed from the other results (about 65% similarity) because of an increase in the number of non-type B CMM samples with positive absorbance values.
Analysis of Type E Samples
The ELISA data for detection of positive type E samples differed little (59 positive out of 60 tests) from the reference method for high or low toxin TPGY samples ( Table 7) . Three of the type E CMM cultures (Beluga, D8-E, and C. butyricum) were nontoxic with the reference method (high and low culture; Table 1 ). However, the ELISA was positive in all 10 laboratories (Table 8) 
a + = Positive ELISA; -= negative ELISA. b $100 MLD/mL by mouse bioassay. c £100 MLD/mL by mouse bioassay. 
a + = Positive ELISA; -= negative ELISA. b $ 100 MLD/mL by mouse bioassay. c # 100 MLD/mL by mouse bioassay. 
a + = Positive ELISA; -= negative ELISA; p/n = one well negative and one well positive. b $ 100 MLD/mL by mouse bioassay. c # 100 MLD/mL by mouse bioassay. 
a + = Positive ELISA; -= negative ELISA; p/n = one well positive and one well negative. b $ 100 MLD/mL by mouse bioassay. c # 100 MLD/mL by mouse bioassay. ( Table 7) . Polymerase chain reaction (PCR) analysis of this strain identified the presence of at least part of the type E toxin gene. The interlaboratory comparison of the ELISA was very good (similarity coefficient $90%). The only exception was Collaborator 4 results with the CMM low toxin samples (similarity coefficient of 72% compared with data of the other collaborators). This difference was due to high absorbance values in some non-type E samples.
Analysis of Type F Samples
Six type F toxin cultures from proteolytic C. botulinum and 5 type F cultures from nonproteolytic C. botulinum were tested ( Table 1 ). The ELISA data for detection of both high and low type F toxin samples from proteolytic strains in TPGY differed little (110 positive out of 114 tests) from the reference method (Table 9 ). The ELISA data for the nonproteolytic cultures in TPGY were also similar to the reference method, except that one sample negative by the reference method was ELISA-positive in all the laboratories. A C. baratii sample was 1 MLD/mL with the reference method and negative by the ELISA in most laboratories. The ELISA also performed similarly to the reference method with type F samples from proteolytic strains grown in CMM (Table 10) . However, few positive ELISA tests were obtained with any of the samples from nonproteolytic strains because of low levels of toxin produced in CMM (Table 10) .
Laboratories reported more false-positive samples (specificity 91%) for the test sample cultures with the ELISA for type F than for the other toxin type analyses (Tables 2002.08A and B). However, the agreement between the ELISA and the reference method was good (91%) when culture supernatants were diluted (low toxin level, Tables 2002.08A and B). The problem of nonspecificity of binding in the ELISA was also evident in the interlaboratory comparisons. Similarity coefficients were as low as 60%, but generally $80%.
Discussion
The purpose of this study was to assess the robustness of an ELISA, in multiple laboratories, for the detection of A, B, E, and F botulinal toxins produced in culture and to compare its performance with that of the mouse bioassay reference method. TPGY and CMM culture media were used because they are the media required for the AOAC Official Method (1). The mouse neutralization assay is usually performed after an end point toxicity of a culture is determined. Usually the assay of a botulinal culture involves the following 3-part analysis: preliminary screening, endpoint toxin determination, and neutralization assay to identify toxin type. Each part requires at least 2 days. In addition, some clostridia produce nonbotulinal toxins that also kill mice. The ELISA is a 1-day assay for the presence of any of the A, B, E, or F toxin types. Use of the ELISA may provide preliminary identification of toxin type in less time than the reference method.
Interlaboratory comparisons demonstrated that, with few exceptions, the data submitted from each collaborating laboratory were similar. All reagents and supplies, including microtiter plates, were provided to the collaborating laboratories. Pre-and post-collaborative studies have shown that plates supplied by a few microtiter plate vendors are acceptable for use in this assay. At this time only the Nunc Immunoplate ll and Dynex Immulon ll (flat-bottom and U-well) have been tested and appear interchangeable. We have not observed plate-to-plate or lot-to-lot disparities with plates from these sources. Standard laboratory equipment, such as pipettors, incubators, plate washers, and plate readers were not provided.
Ten of the 11 collaborators submitted usable data. One collaborator cited problems with a plate washer that resulted in high background absorbance. Collaborators were given no specific instructions on plate washers except that squeeze bottles were not acceptable. Collaborators used equipment available to them, and the washer varied from fully automated to simple hand-held mechanical devices connected to vacuum systems. Investigators using this method should ensure that the washing device available to them results in acceptable background absorbance values.
Previously, this ELISA was determined to have a sensitivity of about 10 MLD/mL (2). These results were confirmed in this study. With some exceptions, the ELISA does not detect botulinal toxin in culture at concentrations <10 MLD/mL.
Although the ELISA method was validated in this study by using botulinal cultural toxins at 2 toxin levels (high and low), the assay was originally designed to test only undiluted or very low dilutions of media. Table 2 shows that the ELISA has high sensitivity (compared to the reference method) in cultures with $100 MLD/mL. Table 1 shows that some of the cultures (types E and F in CMM) possessed a relatively low to zero toxicity with the mouse bioassay reference method. Some of the cultures (unexpectedly) did not meet the prescribed high or low toxicity definitions (10 000 or 100 MLD/mL, respectively) with the reference method. We also tested these lower toxicity samples with the ELISA because there would have been insufficient samples for evaluation, especially for types E and F in CMM. The sensitivity of the ELISA was similar to that of the reference method. In general, toxin production in CMM was lower than in TPGY; therefore, the sensitivities of both the ELISA and the reference methods were lower with CMM samples. Both CMM and TPGY are required for the reference method (1) and, thus, were used for the ELISA.
Although not reflected in this study, some strains of C. botulinum grow more efficiently in CMM than in TPGY (unpublished observation). The ELISA was positive in some of these cases in which the mouse bioassay was negative or of low toxicity, suggesting that in some cultures the ELISA may be more sensitive than the mouse bioassay. However, because specificity of the types E and F ELISA was lower than that for the types A and B ELISA (Tables 2002.08A and B) , cross-reactivity with non-toxin components in the culture may be responsible for a portion of this apparent increase in sensitivity.
All of the TPGY or CMM test cultures (positive with the reference method) would have been positive if tested at the undiluted level except for the type F nonproteolytic culture, C. baratii. The mouse bioassay results for C. baratii showed that this culture produced 10 MLD/mL in TPGY and 1 MLD/mL in CMM. This culture was weakly positive in the FDA Southeast Regional Laboratory before being shipped for the mouse bioassay and to the study laboratories, and was subjected to an extra freeze/thaw cycle before analysis by the collaborating laboratories. Freezing and thawing of this low toxin culture, as well as some of the other low toxin cultures (Table 1) may have reduced the antigenicity of these samples and resulted in lower binding to the ELISA capture antibody.
In general, culture of C. botulinum produces toxin levels >100 MLD/mL (unpublished data) and so would be identified with this ELISA method. The mouse intraperitoneal lethal dose for type A toxin is 0.02 ng. A 100 MLD/mL sample would contain about 2 ng toxin. Arnon et al. (7) estimated that the human lethal oral dose for type A toxin is 70 mg toxin/70 kg body weight. A 1 mg amount of type A toxin in 1 mL culture, therefore, would contain about 50 000 MLD/mL. Thus in this study, the ELISA had a small chance (about 1 in 250) of not detecting a sample containing 10 000 mouse MLD/mL. However, this concentration is only equivalent to about 3´10 -3 human MLD/mL. This small risk will be offset by the ability to rapidly and easily screen more samples. As mentioned above, in no case was any toxic culture undetected because the toxic cultures were detected in at least one of the 2 media (TPGY or CMM) used in the study.
Specificity of the ELISA was quite good (about 95%) with the exception of the type F test. Cross-reactivity was random in all laboratories for cultures of any given toxin type and between types with a few exceptions. One of the proteolytic type F strains (pasteurized crab) cross-reacted with the type E ELISA in most of the laboratories.
Our PCR tests (unpublished data) revealed that this strain contained a fragment of the type E toxin gene, which may explain the cross-reactivity if the entire gene is present and is functional antigenically. The highest cross-reactivity was observed with the type F ELISA with high toxin samples from TPGY ( Table 9 ). The original concentration of type F biotinylated IgG reagent suggested for the study was too high and was changed during the study. Four of the laboratories (2-4 and 9) used the original concentration, and the remaining 6 laboratories used a reduced (50%) biotin concentration. Use of the F biotin reagent at the lower concentration resulted in relatively lower false positives and cross-reactivity with the same level of detection for the type F samples (Tables 9 and  10 ). Cross-reactivity results for Collaborator 4 (a laboratory with higher F biotin concentration) were also much higher than those of the others, accounting for 35% of the total cross-reactivity for all 10 laboratories. Of the nonbotulinal cultures, C. novyi was the most reactive with the ELISA (types A, B, E, and F analyses) and was responsible for most of the cross-reactivity overall. C. novyi accounted for 48% of cross-reactions for the nonbotulinal cultures tested and for 10% of the total cross-reactivity using all the toxic and nontoxic cultures. Because of the unexpected level of false positives obtained with the nonbotulinal cultures (especially C. novyi) we tested 7 more nonbotulinal cultures. C. tetani, C. butyricum, C. difficile, C. subterminale, and 3 more C. sporogenes strains were also prepared in TPGY and CMM and tested with the ELISA. These 7 new nonbotulinal strains that were tested for false-positive reactions were negative in the Study Director's laboratory (data not shown). Although the absorbance level was above background for some of these 7 cultures in undiluted media, it was below the absorbance criterion to be judged as positive. None of the new nonbotulinal cultures reacted with the ELISA at a 1:5 dilution of the culture media.
It is difficult to make a fair comparison of the mouse bioassay and the ELISA using Chi square values. The reference method was not performed in every collaborating laboratory because of the scarcity of laboratories that could receive botulinal cultures, and the potential unethical use of animals in duplicate tests at multiple sites. It was assumed that if a sample was positive or negative by the reference method, the test result would be the same in all 10 collaborating laboratories. However, this assumption may be incorrect since some variability does occur in the reference method at low toxin levels.
Chi square values were highest in the high toxin samples and were mostly due to greater nonspecific binding by other botulinal toxin type samples. Although the Chi square analyses indicated a significant difference between most of the ELISA tests and the reference method, the agreement between the ELISA and the reference method was generally very good (Tables 2002.08A and B).
Collaborators' Comments
Most collaborators reported that working with 4 plates in 1 day was difficult. One of the laboratories examined 2 plates per day instead of 4. Several laboratories used 2 analysts to analyze the 4 plates each day. In some laboratories, the positive controls provided did not reach the recommended level of absorbance for stopping the reaction. Most collaborators reported that they felt more comfortable with the assay as the study progressed. One collaborator felt that the assay would proceed more smoothly if a process sheet were included.
Conclusions
The data show that the ELISA method is useful as a preliminary test for the detection and typing of botulinal toxins produced in culture media with a toxicity >10 MLD/mL. Few if any cultures of C. botulinum would be missed at this very low level of toxin, which is below the low toxin (100 MLD/mL) level samples used in this study. However, because some cross-reactivity with nonbotulinal cultures was observed, samples that are detected with this ELISA must be confirmed by the mouse bioassay.
Recommendation
It is recommended that the amp-ELISA be adopted as Official First Action for the detection of types A, B, E, and F botulinal cultural toxins from TPGY and CMM.
